SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 17:48:12 22/07/2024 BST 5-day change 1st Jan Change
35.74 USD -5.25% Intraday chart for SpringWorks Therapeutics, Inc. -15.07% -2.64%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Sector Update: Health Care Stocks Mixed Premarket Monday MT
Sector Update: Health Care MT
SpringWorks Therapeutics Submits New-Drug Application to FDA for Mirdametinib MT
Springworks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with Nf1-Pn CI
Transcript : SpringWorks Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 02:00 PM
SpringWorks Therapeutics, Inc. Receive Notice of Termination of the Amended and Restated Collaboration and License Agreement with GlaxoSmithKline Intellectual Property Development Ltd CI
Springworks Therapeutics Insider Sold Shares Worth $801,372, According to a Recent SEC Filing MT
Springworks Therapeutics Insider Sold Shares Worth $1,955,113, According to a Recent SEC Filing MT
SpringWorks Therapeutics, Inc. Announces Data to Be Presented at the 2024 American Society of Clinical Oncology Annual Meeting CI
Transcript : SpringWorks Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 03:40 PM
Wedbush Raises SpringWorks Therapeutics' Price Target to $75 From $70, Keeps Outperform Rating MT
SpringWorks Therapeutics Shares Fall After Wider-Than-Expected Q1 Loss MT
Transcript : SpringWorks Therapeutics, Inc., Q1 2024 Earnings Call, May 02, 2024
Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q1 Revenue $21M, vs. Street Est of $13.1M MT
SpringWorks Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Transcript : SpringWorks Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:00 AM
JPMorgan Adjusts Price Target on SpringWorks Therapeutics to $75 From $74, Keeps Overweight Rating MT
HC Wainwright Raises Price Target on SpringWorks Therapeutics to $74 From $73, Maintains Buy Rating MT
SpringWorks Therapeutics Starts Rolling New Drug Application for Prospective Tumor Treatment MT
SpringWorks Therapeutics, Inc. Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN CI
SpringWorks Therapeutics Q4 Net Loss Widens; Full-Year Net Loss Narrows MT
SpringWorks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q4 Revenue $5.4M MT
Wedbush Raises SpringWorks Therapeutics' PT to $70 From $60, Increases Sales Estimates for Ogsiveo, Mirdametinib; Keeps Outperform Rating MT
Wedbush Raises SpringWorks Therapeutics' PT to $60 From $45 on Increased Valuation for Ogsiveo in Desmoid Tumors; Keeps Outperform Rating MT
Chart SpringWorks Therapeutics, Inc.
More charts
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. OGSIVEO (nirogacestat) is the Company's Food and Drug Administration (FDA)-approved therapy. OGSIVEO (nirogacestat) is approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. The Company also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. Its ongoing developments include Nirogacestat for treatment of ovarian granulosa cell tumors, Nirogacestat in combination with B-cell maturation antigen (BCMA)-targeted agents, Mirdametinib Phase 2b ReNeu trial in NF1-PN and Brimarafenib (BGB-3245). The Company's early-stage pipeline includes SW-682, an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluated in Hippo-mutant solid tumors.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
37.72 USD
Average target price
66.7 USD
Spread / Average Target
+76.82%
Consensus
  1. Stock Market
  2. Equities
  3. SWTX Stock
  4. News SpringWorks Therapeutics, Inc.
  5. SpringWorks Therapeutics Starts Rolling New Drug Application for Prospective Tumor Treatment